[Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease]
- PMID: 29027424
- DOI: 10.19540/j.cnki.cjcmm.20170121.021
[Research progress on therapeutic targets of active components in Chinese herbs for treatment of nonalcoholic fatty liver disease]
Abstract
Nonalcoholic fatty liver disease(NAFLD) is a kind of metabolic liver injury, which is closely associated with insulin resistance and genetic susceptibility. Traditional Chinese herbs used in the treatment of nonalcoholic fatty liver disease are widely investigated in recent years. A series of recent studies show that the effects of the active components in traditional Chinese herbs on NAFLD are associated with activating AMPK signaling pathway, improving insulin resistance, modulating the activity and expression of peroxisome proliferator-activated receptor γ, antioxidant and anti-inflammatory activities and regulating intestinal flora. In this review, the potential therapeutic targets of the active components from traditional Chinese herbs for NAFLD would be summarized to provide a new thought for further research and clinical treatment of nonalcoholic fatty liver disease.
Keywords: active components; nonalcoholic fatty liver disease; therapeutic targets.
Copyright© by the Chinese Pharmaceutical Association.
Conflict of interest statement
The authors of this article and the planning committee members and staff have no relevant financial relationships with commercial interests to disclose.
Similar articles
-
Protective Effect of Fuzi Lizhong Decoction against Non-alcoholic Fatty Liver Disease via Anti-inflammatory Response through Regulating p53 and PPARG Signaling.Biol Pharm Bull. 2020;43(11):1626-1633. doi: 10.1248/bpb.b20-00053. Biol Pharm Bull. 2020. PMID: 33132309
-
Research progress in use of traditional Chinese medicine monomer for treatment of non-alcoholic fatty liver disease.Eur J Pharmacol. 2021 May 5;898:173976. doi: 10.1016/j.ejphar.2021.173976. Epub 2021 Feb 24. Eur J Pharmacol. 2021. PMID: 33639194 Review.
-
PPAR-γ signaling in nonalcoholic fatty liver disease: Pathogenesis and therapeutic targets.Pharmacol Ther. 2023 May;245:108391. doi: 10.1016/j.pharmthera.2023.108391. Epub 2023 Mar 22. Pharmacol Ther. 2023. PMID: 36963510 Review.
-
Isobaric tags for relative and absolute quantitation (iTRAQ)-based proteomics for the investigation of the effect of Hugan Qingzhi on non-alcoholic fatty liver disease in rats.J Ethnopharmacol. 2018 Feb 15;212:208-215. doi: 10.1016/j.jep.2017.09.016. Epub 2017 Oct 13. J Ethnopharmacol. 2018. PMID: 29031784
-
Monascin and ankaflavin act as natural AMPK activators with PPARα agonist activity to down-regulate nonalcoholic steatohepatitis in high-fat diet-fed C57BL/6 mice.Food Chem Toxicol. 2014 Feb;64:94-103. doi: 10.1016/j.fct.2013.11.015. Epub 2013 Nov 22. Food Chem Toxicol. 2014. PMID: 24275089
Cited by
-
Flavonones from Penthorum chinense Ameliorate Hepatic Steatosis by Activating the SIRT1/AMPK Pathway in HepG2 Cells.Int J Mol Sci. 2018 Aug 28;19(9):2555. doi: 10.3390/ijms19092555. Int J Mol Sci. 2018. PMID: 30154382 Free PMC article.
-
Salvia-Nelumbinis naturalis improves lipid metabolism of NAFLD by regulating the SIRT1/AMPK signaling pathway.BMC Complement Med Ther. 2022 Aug 9;22(1):213. doi: 10.1186/s12906-022-03697-9. BMC Complement Med Ther. 2022. PMID: 35945571 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical